2024 | Issue 6

Physicians office Resource

Resources for You, Your Patients, & Your Practice

Early Detection and Management of Chronic Conditions

with DCA Vantage® and CLINITEK Status®+ Analyzers

MDescapes: Secrets Cap Cana Discovering Paradise | PAGE 32



How to Create a Medical Empire Part 2: Business Opportunities in Healthcare PAGE 14

Screening Diabetic Patients with Wounds for PAD and Neuropathy is a Standard of Care PAGE 30



A Broad Range of Respiratory Point-of-Care Tests

We recognize your **passion** for providing high quality care to patients displaying symptoms associated with respiratory infections, and we appreciate your efforts and **resiliency** working to reduce the rapid spread of these infections.

We are committed to providing **high quality, molecular and antigen point-of-care tests for detecting the most common respiratory infections**, so you can get the answers fast and your patients back to doing what they love.

Like you, we understand there is a patient behind every answer—and that's what matters most.

Learn more about our tests for Flu A&B, COVID-19, Strep A, and more.


For more information, call 800-332-1042, or scan QR code.



The Aptitude Metrix® COVID-19 Test is provided by SEKISUI Diagnostics

The Metrix COVID-19, OSOM COVID-19 Antigen Rapid Test, and OSOM Flu SARS-CoV-2 Combo Test have not been FDA cleared or approved. They are authorized by FDA under an EUA for use by authorized laboratories. The Metrix COVID-19 has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The OSOM COVID-19 Antigen Rapid Test has been authorized only for the detection of SARS-CoV-2 antigen, not for any other viruses or pathogens. OSOM Flu SARS-CoV-2 Combo Test has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens. The use of these products are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

© 2024 SEKISUI Diagnostics, LLC. All rights reserved. OSOM® is a registered trademark of SEKISUI Diagnostics, LLC. Because every result matters™ is a trademark of SEKISUI Diagnostics, LLC. Metrix® is a registered trademark of Aptitude Medical Systems Inc.



Getting the most from this guide

There are two simple ways to request information about the products and services found in Physicians Office Resource.

1. Go to www.PhysiciansOfficeResource.com and enter the four-digit reference number found next to the product or service into the search field, then request additional information, schedule a demo, or speak with a sales agent all with just a simple click of a button.

2. Find the Business Reply Card in this issue, circle the desired reference numbers, complete the form, and drop into any USPS mailbox. A representative will contact you as quickly as possible to answer your questions.

www.PhysiciansOfficeResource.com

Physicians office Resource

PUBLISHED BY
Medical Education Resources, LLC

PUBLISHER
Aaron R. Medaris
amedaris@physiciansofficeresource.com

CEO
Andrew C. Nimmo
acnimmo@physiciansofficeresource.com

PRESIDENT
John D. Pasquale
jpasquale@pharmaconnect.com

BUSINESS MANAGER
Marci J. Hills
mhills@physiciansofficeresource.com

TRAVEL EDITOR
Brandi L. Brower

EDITORIAL BOARD
Michael Paquin, FHIMSS
Barry Craig, MLT (NCA), CLC

STAFF WRITER
Dylan J. Chadwick

CREATIVE DIRECTOR
PRODUCTION MANAGER
Jessica Elmer

Copyright ©2024

To continue your free subscription of Physicians Office Resource magazine, please fill out the Business Reply Card (BRC) located within this magazine and drop in any United States Post Office mailbox.

If you are a manufacturer of medical products or provide services to medical professionals and would like to advertise your products or services to the nation's top physicians doing in-office testing, call 801-380-6094 or visit: POR.io for more information.

TABLE OF CONTENTS

Early Detection and Management of Chronic Conditions

with DCA Vantage® and
CLINITEK Status®+ Analyzers



DCA VANTAGE® AND CLINITEK® STATUS ANALYZERS

From Siemens Healthineers

Siemens Healthineers DCA Vantage® and CLINITEK Status® family of analyzers provide Hemoglobin A1c (HbA1c) and albumin-to-creatinine ratio (ACR) testing at the point of care. Monitor glycemic control in patients with diabetes and screening for kidney disease in patients at-risk, in-office. Enable real-time consultation, eliminating loss to follow-up. Improve the patient experience and overall outcome by providing actionable results in minutes.

CLIA-WAIVED: DCA HBA1C; CLINITEK MICROALBUMIN 2 (ACR), CLIA MODERATE COMPLEXITY: DCA® MICROALBUMIN/CREATININE (ACR)

View Brochures, Videos & More at POR.io Enter Number **4003** or **4004** in the Search Area

14

How to Create a Medical Empire Part 2: Business Opportunities in Healthcare

This piece aims to provide an overview of the various healthcare business categories that a novice investor can explore

30

Screening Diabetic Patients with Wounds for PAD and Neuropathy is a Standard of Care

Lower-extremity amputation has been reported to be the most feared complication by patients experiencing diabetic foot problems.

32

MDescapes: Secrets Cap Cana—Discovering Paradise

Nestled along the picturesque coastline of the Dominican Republic, lies a sanctuary of luxury and tranquility – Secrets Cap Cana.

PHOTOMETRIC ELECTROLYTES for CHEMISTRY ANALYZERS

Electrolytes can now run just like other chemistries. Avoid extra cost and maintenance associated with ISE.



BENCHTOP

Diazyme DZ-Lite™ c270

4005

up to **270** photometric tests/hr

60+ CLIA moderate complexity assays

Including:

- ✓ Cancer Markers
- ✓ Cardiovascular Markers
- ✓ Coagulation Markers
- ✓ Diabetic Markers
- ✓ Inflammatory Markers
- ✓ Liver Markers
- ✓ Renal / Pancreatic Markers
- ✓ Sepsis Markers
- ✓ Vitamin Markers
- ✓ Photometric Electrolytes
- ✓ Drugs of Abuse



FLOOR MODEL

CLC 800™

4006

up to **400** photometric tests/hr

30+ CLIA moderate complexity assays

Choose ISE or Photometric Electrolytes

CAROLINA LIQUID CHEMISTRIES CORP.

call 877-722-8910

carolinachemistries.com

Installation and training included



DIAZYME DZ-LITE™ C270 BENCHTOP GENERAL/SPECIAL CHEMISTRIES + DRUG SCREENS

From Carolina Liquid Chemistries

A fully-automated, open system, benchtop clinical chemistry analyzer with throughput up to 270 tests/hour, 36 reagent positions, and 30 sample positions. It features a menu of over 60 CLIA moderate complexity assays, including cancer markers, cardiovascular markers, coagulation markers, diabetic markers, inflammatory markers, liver markers, renal/pancreatic markers, sepsis markers, vitamin markers, photometric electrolytes, and drugs of abuse. To learn more, visit https://www.carolinachemistries.com/products/dz-lite-c270-benchtop-chemistry-analyzer/.

View Brochures, Videos & More at POR.io
Enter Number **4007** in the Search Area

FULL COMPLEMENT OF CLIA-WAIVED BLOOD CHEMISTRY TESTS PICCOLO XPRESS® CHEMISTRY ANALYZER

From Abbott Point of Care

The Piccolo Xpress Chemistry Analyzer provides physician offices with lab-accurate results for a broad range of CLIA-waived general chemistry tests, including metabolic panels, lipids, live, and kidney function, and more with just 100 microliters of blood. Easy to use, the PIccolo Xpress provides results during a patient's visit, accelerating treatment decisions, increasing efficiency, and supporting patient satisfaction. Automated quality control on every test helps ensure accuracy.

View Brochures, Videos & More at POR.io
Enter Number **4008** in the Search Area





EASYRA® BENCHTOP CHEMISTRIES + DRUGS

From Carolina Liquid Chemistries

When starting a lab, look no further. With a CLIA moderately complex menu of 35 general chemistries and 14 urine drug screens, the EasyRA is well-suited for oncology, rheumatology, and multi-specialty practices needing a benchtop clinical chemistry analyzer. The EasyRA offers photometric throughput of 240+ tests/hr (up to 480 tests/hr with ISE) and STAT samples in under 8 minutes. This all-in-one system is easy to learn and easy to operate.

View Brochures, Videos & More at POR.io
Enter Number **4009** in the Search Area

LumiraDx™

Not all Antigen Tests are Created Equal



The LumiraDx SARS-CoV-2 Ag test utilizes next-generation microfluidic technology, bringing lab-comparable performance to the point of care.

- 97.6% positive agreement to RT-PCR in patients up to 12 days following symptom onset • Microfluidic immunofluorescence assay
- Easy to use • Results in minutes • Small, low-waste consumable
- CLIA Waived*



4010

Scan to learn more.
LumiraDx.com

*The LumiraDx SARS-CoV-2 Ag test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This product has not been FDA cleared or approved but has been authorized by FDA under an EUA for use by authorized laboratories. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the declaration is terminated, or authorization is revoked sooner. S-COM-ART-02381 R3 2022/11



METRIX® COVID-19 TEST – A MOLECULAR LAB ANYWHERE AND EVERYWHERE

From Sekisui

The Metrix® COVID-19 is a novel technology includes clinical claims for symptomatic and asymptomatic individuals, along with dual-sample types for nasal or saliva, allowing for an enhanced point-of-care testing experience. The reader is compact and robust, it's ideal for professional use in diverse locations, including clinics and mobile health units. It's a maintenance free device with no calibration step required.

View Brochures, Videos & More at POR.io
Enter Number **4011** in the Search Area

WHY COMPROMISE? FAST AND RELIABLE RESULTS ARE NOW DELIVERED AT THE POINT OF CARE.

From LumiraDx

Introducing the next generation in point-of-care diagnostics. With a growing menu of tests, LumiraDx uses a simple process that allows for more time with your patients by using microfluidic technology that delivers results in minutes. Learn more about rapid COVID-19 diagnostic solutions for your physician office at LumiraDx.com.

View Brochures, Videos & More at POR.io
Enter Number **4012** in the Search Area





BE PREPARED FOR RESPIRATORY SEASONS WITH THE OSOM® COVID-19 ANTIGEN RAPID TEST


From Sekisui

The OSOM® COVID-19 Antigen Rapid Test is a lateral flow immunoassay that detects the SARS-CoV-2 nucleocapsid protein with a nasal swab in only 15 minutes at the point-of-care. The test is intended to be used by healthcare professionals or operators on patients suspected of COVID-19 within the first 7 days of symptom onset. The clinical performance compares favorably against polymerase chain reaction methodology, with a positive percent agreement of 95.1% and a negative percent agreement of 97%.

View Brochures, Videos & More at POR.io
Enter Number **4013** in the Search Area

OSOM® COVID-19 Antigen Rapid Test has not been FDA cleared or approved. It is authorized by FDA under an EUA for prescription use only. It has been authorized only for the detection of SARS-CoV-2 antigen, not for any other viruses or pathogens and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C S360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

Personal finance education, tailored to you.



Get our mobile app for free.

@scrubmoneyorg
scrubmoney.org



EARLY DETECTION AND MANAGEMENT OF CHRONIC CONDITIONS WITH DCA VANTAGE® AND CLINITEK STATUS®+ ANALYZERS

From Siemens Healthineers

Siemens Healthineers DCA Vantage® and CLINITEK Status® family of analyzers provide Hemoglobin A1c (HbA1c) and albumin-to-creatinine ratio (ACR) testing at the point of care. Monitor glycemic control in patients with diabetes and screening for kidney disease in patients at-risk, in-office. Enable real-time consultation, eliminating loss to follow-up. Improve the patient experience and overall outcome by providing actionable results in minutes.

CLIA-waived: DCA HbA1c; CLINITEK Microalbumin 2 (ACR)
CLIA Moderate Complexity: DCA® Microalbumin/Creatinine (ACR)

View Brochures, Videos & More at POR.io
Enter Number **4015** in the Search Area

QUANTAFLO® PAD

From Semler Scientific

QuantaFlo® PAD is an easy to use, accurate, point of care, non-invasive solution that aids in the early detection of peripheral arterial disease (PAD). This FDA cleared device can be administered by a medical aide in less than 5 minutes. As published in the Journal of Vascular Surgery and the American Journal of Preventive Medicine, QuantaFlo detected undiagnosed PAD in 31.6% of patients +65.1 QuantaFlo is portable and integrates with other technologies and platforms. It is ideal for both home and clinic environments.

1. Smolderen KG, Ameli O, Chaisson CE, Heath K, Mena-Hurtado C. Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events, AJPM Focus (2022), https://doi.org/10.1016/j.focus.2022.100016

View Brochures, Videos & More at POR.io
Enter Number **4016** in the Search Area






NOVA PRIMARY BLOOD GLUCOSE REFERENCE ANALYZER

From Nova Biomedical

The U.S. FDA has cleared Nova Primary as a blood glucose reference analyzer that fills the need for a new reference analyzer to replace the YSI STAT PLUS 2300 (YSI, Inc., Yellow Springs, OH). Manufacturers of blood glucose measuring devices and clinical diabetes researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, YSI, Inc. no longer supports the analyzer, and its discontinuation has left a critical industry void. With today's FDA clearance, Nova Primary from Nova Biomedical is now available in the U.S. and worldwide.

View Brochures, Videos & More at POR.io
Enter Number **4017** in the Search Area

vyepti®
(eptinezumab-jjmr)
100 mg/mL Injection for IV



VYEPTI is indicated for the preventive treatment of migraine in adults.[1]

***The vicious cycle is defined as more frequent migraine days with the continued increasing need for acute medications over time.[2,3]**

Please scan the QR code to visit the VYEPTI Sponsored Resource Page on ConnectRX.com

Learn more at vyeptihcp.com

During the 6-month chronic migraine pivotal study,

40% of patients treated with VYEPTI® (eptinezumab-jjmr) 300 mg were



100%

migraine free for a month or more
vs 22% with placebo[1,7*†‡§]

During a 6-month period, 35% of patients treated with VYEPTI 100 mg were 100% migraine free for a month or more vs 22% with placebo.[1,7*†‡§]

‡Post hoc analysis.

On average, 26.7% (100mg) and 33.1% (300mg) of patients with chronic migraine had a ≥75% response rate over weeks 1-12 vs 15.0% on placebo, p<0.001.[1**]

Primary endpoint results[1,5]

In PROMISE-2, patients with chronic migraine experienced on average 23.1 (VYEPTI 100 mg) and 24.6 (VYEPTI 300 mg) fewer migraine days, over weeks 1-12, vs 16.8 with placebo¶ (baseline ~16.1 mean monthly migraine days (MMD); p<0.001).**

Patients experienced a 52% reduction in mean acute medication days# on VYEPTI 300 mg over weeks 1-12[5,6]

In patients with chronic migraine, VYEPTI 100 mg†† and 300 mg§§ reduced acute medication days from 6.6 to 3.3 and 6.7 to 3.2 days/months, respectively (vs 6.2 to 4.3 days/months for placebo) (Weeks 1-12).[4#]

The efficacy of VYEPTI 100mg and 300mg was evaluated as a preventive treatment for episodic‡‡ migraine in PROMISE-1 and for chronic migraine[1] in the PROMISE-2 pivotal trials, see vyeptihcp.com/efficacy.

100 mg is the recommended dose. Some patients may benefit from the approved 300 mg dose.

*A migraine-free month was defined as a consecutive 28-day period with the first day of dosing used as the reference point, in which a patient experienced no migraine.
†Baseline ~16.1 mean monthly migraine days.
§VYEPTI 300 mg: n=350; VYEPTI 100 mg: n=356; placebo: n=366.
¶Calculated by multiplying the mean change from baseline in mean MMD by 3 months (VYEPTI 100 mg 7.7; VYEPTI 300 mg 8.2; placebo, 5.6).
**Chronic migraine: ≥15 to ≤26 headache days a month with ≥8 being migraine days.
#An acute migraine medication day is a day with any triptan or ergotamine use.
††Prespecified endpoint, exploratory analysis.
§§ Key secondary endpoint.
‡‡Episodic migraine: 4 to 14 monthly headache days of which at least 4 were migraine days.

©2024 Lundbeck. All rights reserved. VYEPTI is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101464

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see a Brief Summary of the Full Prescribing Information on the following page.

References: 1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc. **2.** Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. *Eur J Neurol.* 2020;27(7):1102-1116. **3.** Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd ed. *Cephalalgia.* 2018;38(1):1-211. **4.** Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-2) study. *J Headache Pain.* 2020;21(1):120. **5.** Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. *Neurology.* 2020;94(13):e1365-e1377. **6.** Data on file. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc. **7.** Winner P, McAllister P, Cady R, Snapinn S, Hirman J, Kassel E. Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society (AHS); July 11-14, 2019; Philadelphia, PA. P217LB.

VYEPTI® (eptinezumab-jjmr) injection, for intravenous use

Brief Summary of Prescribing Information

(See package insert for Full Prescribing Information or visit www.vyeptihcp.com)

INDICATIONS AND USAGE

VYEPTI® (eptinezumab-jjmr) is indicated for the preventive treatment of migraine in adults.

CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients in VYEPTI. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Hypersensitivity Reactions.

Clinical Trials Experience: Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of VYEPTI was evaluated in 2076 patients with migraine who received at least one dose of VYEPTI, representing 1615 patient-years of exposure; of these, 1524 patients were exposed to 100 mg or 300 mg. Across all doses, 1872 patients were exposed for at least 6 months and 991 patients were exposed for 12 months. In the placebo-controlled clinical studies (Study 1 and Study 2) of 1372 patients, 579 patients received at least one dose of VYEPTI 100 mg, 574 patients received at least one dose of VYEPTI 300 mg, and 588 patients received placebo. Approximately 86% were female, 89% were white, and the mean age was 40.4 years at study entry.

The most common (incidence at least 2% and at least 2% greater than placebo) adverse reactions in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

Table 1 summarizes the adverse reactions that occurred during Study 1 and Study 2.

Table 1. Adverse Reactions Occurring with an Incidence of at Least 2% for VYEPTI and at Least 2% Greater than Placebo in Studies 1 and 2

Adverse Reactions	VYEPTI 100 mg N=579 %	VYEPTI 300 mg N=574 %	Placebo N=588 %
Nasopharyngitis	6	8	6
Hypersensitivity reactions*	1	2	0

*Hypersensitivity reactions includes multiple related adverse event terms, such as hypersensitivity, pruritus, and flushing/hot flush that occurred on the day of dosing.

In Study 1 and Study 2, 1.9% of patients treated with VYEPTI discontinued treatment because of adverse reactions.

Immunogenicity:

As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to eptinezumab-jjmr in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.

In patients receiving VYEPTI 100 mg or 300 mg every 3 months, the incidence of anti-eptinezumab-jjmr antibody development in Study 1 (up to 56 weeks) was 20.6% (92/447), and 41.3% (38/92) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. In Study 2 (up to 32 weeks), the incidence of anti-eptinezumab-jjmr antibody development was 18.3% (129/706), and 34.9% (45/129) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies. In an open-label study with 84 weeks of treatment, 18% (23/128) of patients developed anti-eptinezumab-jjmr antibodies, and 39% (9/23) of those patients developed anti-eptinezumab-jjmr neutralizing antibodies.

Although the results from both studies showed no clear evidence of an impact from development of anti-eptinezumab-jjmr antibodies, including neutralizing antibodies, on the safety and efficacy profiles of VYEPTI, the available data are too limited to make definitive conclusions.

Postmarketing Experience: The following adverse reactions have been identified during postapproval use of VYEPTI. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Immune System Disorders: Anaphylaxis

General Disorders and Administration Site Conditions: Fatigue

USE IN SPECIFIC POPULATIONS

Pregnancy: Risk Summary - There are no adequate data on developmental risks associated with the use of VYEPTI in pregnant women. No adverse developmental effects were observed following administration of eptinezumab-jjmr to pregnant animals at doses greater than those used clinically *[see Data]*.

In the U.S. general population, the estimated background risk of major birth defects and miscarriages in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively. The estimated rate of major birth defects (2.2%-2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.

Clinical Considerations - *Disease-Associated Maternal and/or Embryo/Fetal Risk:* Published data have suggested that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy.

Data - *Animal Data:* When eptinezumab-jjmr (0, 75, or 150 mg/kg) was administered weekly to female rats and rabbits by intravenous injection throughout organogenesis, no adverse effects on embryofetal development were observed. The higher dose tested (150 mg/kg) is 30 times the maximum recommended human dose (MRHD) of 300 mg, on a body weight basis (mg/kg).

When eptinezumab-jjmr (0, 75, or 150 mg/kg) was administered weekly to female rats throughout pregnancy and lactation, no adverse effects on pre- and postnatal development were observed. The higher dose tested (150 mg/kg) is 30 times the MRHD, on a mg/kg basis.

Lactation: Risk Summary - There are no data on the presence of eptinezumab-jjmr in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYEPTI and any potential adverse effects on the breastfed infant from VYEPTI or from the underlying maternal condition.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.

Geriatric Use: Clinical studies of VYEPTI did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

CLINICAL PHARMACOLOGY

Pharmacokinetics: Specific Populations

A population pharmacokinetic analysis assessing the effects of age, race, sex, and body weight did not suggest any clinically significant impact of these covariates on eptinezumab exposures.

Patients with Renal or Hepatic Impairment: No dedicated studies were conducted to assess the effects of renal or hepatic impairment on the pharmacokinetics of eptinezumab-jjmr. However, hepatic or renal impairment is not expected to affect the pharmacokinetics of eptinezumab-jjmr. A population pharmacokinetic analysis of integrated data from eptinezumab-jjmr clinical studies did not reveal clinically significant impact on pharmacokinetics of patients with hepatic or renal impairment.

Drug Interaction Studies

P450 Enzymes - Eptinezumab-jjmr is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.

Sumatriptan - The co-administration of a single dose of 300 mg eptinezumab-jjmr administered as an intravenous infusion (over a period of 1 hour ± 15 min) with a single dose of 6 mg sumatriptan administered subcutaneously did not significantly influence the pharmacokinetics of eptinezumab-jjmr or sumatriptan.

Manufactured by:
Lundbeck Seattle BioPharmaceuticals, Inc.
11804 North Creek Parkway South
Bothell, WA 98011 USA
U.S. License No. 2097

Vyepti is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc.
October 2022 EPT-L-100014



PART 2 OF A 6 PART SERIES

HOW TO CREATE A MEDICAL EMPIRE PART 2: Business Opportunities in Healthcare

BY DR. SHAKEEL AHMED

FOR PART 1 OF THIS SERIES PLEASE VISIT
PhysiciansOfficeResource.com/articles



"Success usually comes to those who are too busy to be looking for it."

— HENRY DAVID THOREAU

After outlining the fundamental principles necessary for success in business in my initial article, this piece aims to provide an overview of the various healthcare business categories that a novice investor can explore. This summary highlights the different options available, serving as a foundational guide. Subsequent chapters will offer in-depth insights into each category, providing a detailed analysis to help investors make informed decisions about their investments.

In no specific order of importance or profitability, here are some of the primary business options available to healthcare entrepreneurs:

1 - Establish Your Own Practice:

Starting your own medical practice is a pivotal step in laying the foundation of your future enterprise. While it follows a traditional path, the potential for growth and innovation within this route is vast. It goes beyond merely managing a practice focused on accounting and medical care; it becomes the cornerstone of your entrepreneurial ambitions. This foundational base is not only where you begin but also a driving force for future expansions into diverse business ventures.

Consider the example of Dr. Patrick Soon-Shiong, who started his career as a surgeon before launching a medical practice that focused on transplant surgeries. This hands-on experience laid the groundwork for his later ventures, leading him to develop and commercialize the revolutionary cancer drug Abraxane, and ultimately founding NantWorks, a multinational conglomerate of healthcare companies. Dr. Soon-Shiong's journey from practicing surgeon to entrepreneur underscores how starting a medical practice can ignite a broader entrepreneurial journey.

Another example is Dr. Howard Murad, who established a dermatology practice that eventually led him to create his own skincare line, Murad. Starting with a small practice allowed Dr. Murad to understand the gaps in skincare products available to his patients, inspiring him to develop his own line that addressed these needs directly. His practice acted as a testing ground for his products and a springboard for his brand, now a globally recognized skincare company.

Establishing a medical practice provides firsthand experience in running a healthcare business, managing finances, leading a team, and understanding patient needs—all invaluable lessons that will support your future endeavors. By mastering this foundational skill set, you will be better equipped to navigate the complexities of various industries, positioning yourself as a versatile leader in the entrepreneurial world.

A medical practice offers exposure to the full spectrum of business operations, from navigating healthcare regulations and managing billing systems to hiring and overseeing staff. These skills are transferable and invaluable in virtually any business venture. For instance, Dr. Tom Price transitioned from managing his own orthopedic practice into politics, eventually becoming the U.S. Secretary of Health and Human Services. His medical practice experience gave him deep insights into healthcare systems, influencing his policy perspectives.

By starting your own practice, you not only gain direct clinical experience but also acquire a holistic understanding of healthcare business operations. This experience builds a strong foundation for launching further ventures, whether in related medical fields or entirely new industries. It transforms a traditional path into a springboard for innovative ideas and diverse opportunities, empowering you to navigate the entrepreneurial landscape confidently and successfully.

2 - Launch a Multi-Specialty Group:
Expanding your influence in the medical field often means taking bold steps, such as establishing a multi-specialty group. This ambitious endeavor allows for a dynamic synergy among healthcare professionals from various disciplines, creating a comprehensive healthcare ecosystem. The proverb "a journey of a thousand miles begins with a single step" holds true here, as a partnership of just two specialists can ignite a powerful collaboration that lays the groundwork for a much larger enterprise.

One notable example is Johns Hopkins Medicine. Founded by John Shaw Billings and William Osler in the late 19th century, the institution began as a teaching hospital with a comprehensive vision for integrating education, research, and patient care. Their collaboration fostered the development of one of the world's leading multi-specialty academic medical centers, which now includes the School of Medicine, multiple hospitals, and numerous outpatient facilities. This multi-specialty approach has enabled Johns Hopkins to provide state-of-the-art care across many specialties, from neurology to oncology, while also advancing medical research and education.

Another prominent example is Cleveland Clinic, established in 1921 by four physicians: George Crile, Frank Bunts, William Lower, and John Phillips. Initially a small medical practice, the group aimed to combine specialists' expertise into a cohesive team that could offer comprehensive care. This vision allowed Cleveland Clinic to grow into one of the world's largest multi-specialty group practices, known for its innovative patient care and research initiatives. The clinic's continued success illustrates how a strong foundational collaboration can lead to extensive growth and innovation.

By beginning with a partnership, you set the stage to build a diverse network of expertise that caters to a broader patient base. This early collaboration opens the doors to offer a wider array of medical services, thereby enhancing the value proposition to patients. For example, the Permanente Medical Group, the physician group behind the Kaiser Permanente network, is one of the largest multi-specialty groups in the United States. Its collaborative model integrates primary care with specialty services, allowing it to tap into supplementary revenue streams and diversify its portfolio to include a broad range of specialties.

The potential for growth is immense. Starting with just a couple of specialists creates opportunities to expand service offerings, attract top-tier talent from various fields, and integrate cutting-edge medical technologies. Over time, the multi-specialty group can evolve into a robust network with significant influence, potentially collaborating with hospitals, research institutions, and other healthcare entities. For instance, Mayo Clinic's partnership with Arizona State University to establish a research-focused medical school reflects this expansive vision, transforming a humble beginning into a thriving, multidimensional healthcare powerhouse driven by collaboration and a shared mission to provide the best possible care.

3 - Venture into Medical Product Development:
An often-underestimated yet highly lucrative avenue within the healthcare sector is the development and commercialization of medical products. This includes a wide array of innovations ranging from pharmaceuticals to cutting-edge medical devices, all of which are in high demand due to the continuous evolution of healthcare needs and technological advancements. The global market for medical products is immense and offers numerous opportunities for those with the foresight to enter this field.

Establishing a company dedicated to developing medical products or partnering with an established entity can unlock numerous opportunities. The healthcare industry is continually evolving, with medical knowledge doubling approximately every 73 days, according to recent reports. Staying up-to-date with technological advancements in medical science provides a distinct advantage for medical professionals, offering the potential to identify unmet needs and pioneer innovative solutions.

A prime example of a successful venture into medical product development is Intuitive Surgical. The company started as a small team of engineers with a vision to transform surgery. They developed the da Vinci Surgical System, a robotic platform that has revolutionized minimally invasive surgery by enhancing precision and control. By addressing the unmet need for more advanced surgical tools, Intuitive Surgical has created a multi-billion-dollar business that continues to innovate and expand.

Another example is Gilead Sciences, which began as a small biotechnology company focused on developing antiviral drugs. By investing heavily in research and development, Gilead created groundbreaking antiviral medications that have dramatically improved the treatment of HIV/AIDS and hepatitis C. The company's products have saved countless lives, and its success illustrates the vast potential of investing in innovative pharmaceutical development.

Launching a startup in medical product development requires a multidisciplinary approach, blending medical expertise with engineering, regulatory knowledge, and business acumen. I must add, such a venture necessitates rigorous research and development, meticulous adherence to regulatory standards, and a keen understanding of

THE POWER TO DETECT THE HIDDEN THREAT OF PERIPHERAL ARTERIAL DISEASE (PAD)



"PAD IS ASYMPTOMATIC IN 75% OF ELDERLY PATIENTS." [1]

IN PRIMARY CARE: "THE RISK OF MORTALITY WAS SIMILAR IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH PAD" [2]

Semler Scientific

BOOK YOUR FREE DEMO
CONTACT US TODAY AT 888-340-4881, 5
OR INFO@SEMLERSCIENTIFIC.COM

SEMLERSCIENTIFIC.COM

1. Sillesen, H., & Falk, E. (2011). Peripheral artery disease (PAD) screening in the asymptomatic population: why, how, and who?. Current atherosclerosis reports, 13(5), 390–395. https://doi.org/10.1007/s11883-011-0196-x
2. Diehm, C., Allenberg, J. R., Pittrow, D., Mahn, M., Tepohl, G., Haberl, R. L., Darius, H., Burghaus, I., Trampisch, H. J., & German Epidemiological Trial on Ankle Brachial Index Study Group (2009). Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation, 120(21), 2053–2061. https://doi.org/10.1161/CIRCULATIONAHA.109.865600

ML00190 Rev A

market demands. Having said that, for those with the right expertise and vision, there is immense potential to create products that revolutionize patient care and generate substantial financial returns.

For instance, Edwards Lifesciences, a leading innovator in heart valve technology, developed the first transcatheter aortic valve replacement (TAVR). This less invasive procedure has transformed the treatment of heart valve disease, making it accessible to patients who are not candidates for open-heart surgery. Edwards Lifesciences' success demonstrates how identifying unmet needs and investing in research can lead to transformative medical products.

To truly capitalize on this opportunity, it's vital to keep a finger on the pulse of emerging trends, regulatory changes, and technological breakthroughs. This vigilance, combined with a deep understanding of medical needs and an entrepreneurial spirit, will position you uniquely to develop and launch products that will meet the needs of healthcare providers and patients alike, ensuring a substantial return on investment.

4 - Invest in Healthcare Enterprises:

Investing in healthcare enterprises offers a dynamic and lucrative pathway for diversifying and growing your portfolio. With the healthcare sector projected to expand continuously, driven by an aging population and rapid medical advancements, there is immense potential for substantial returns. The landscape is brimming with opportunities, ranging from direct investments in healthcare companies to indirect investments through healthcare-focused mutual funds or exchange-traded funds (ETFs).

Direct investment in healthcare companies involves allocating capital to companies at the forefront of medical innovation and healthcare delivery. These could include biotechnology firms developing revolutionary gene therapies, medical device companies pioneering advanced diagnostic tools, or pharmaceutical companies researching new treatments. By carefully analyzing the market and selecting companies with a strong pipeline and innovative potential, investors can benefit from both short-term gains and long-term growth.

An example of this strategy is investing in a biotech startup focused on developing CAR-T therapy, a cutting-edge cancer treatment that modifies a patient's own cells to target and destroy cancer cells. With the increasing success rates and potential of this technology, investing early in such startups has the potential to yield significant returns if they achieve regulatory approval and commercial success.

For those seeking broader exposure, indirect investment through healthcare-focused mutual funds or ETFs is an attractive option. These investment vehicles pool resources to invest in a diversified portfolio of healthcare companies, thereby spreading risk while capturing sector-wide growth. They offer an accessible route to tap into the robust healthcare market, covering everything from hospital operators to medical technology companies and pharmaceutical giants.

Consider the iShares U.S. Healthcare ETF (IYH) as an example. This ETF provides exposure to large and mid-sized U.S. healthcare companies, including industry leaders in pharmaceuticals, medical devices, and health insurance. The diversified nature of the ETF allows investors to benefit from the collective growth of the healthcare sector while mitigating risks associated with investing in individual companies.

The potential of investing in healthcare is underscored by the sector's resilience and ability to thrive even in uncertain economic times. Healthcare is an essential service, and its growth is fueled by demographic shifts and advancements in medical technology. This creates a steady demand for healthcare products and services, making the sector a relatively stable investment.

To maximize returns, investors should closely follow healthcare trends, regulatory changes, and advancements in medical research. By identifying emerging opportunities and aligning investments with future industry developments, investors can position themselves to benefit from the sector's growth while contributing to improved healthcare outcomes.

5 - Offer Administrative and Consultative Services:

Leveraging your extensive medical knowledge to provide administrative and consultative services can be a highly lucrative way to capitalize on your expertise within healthcare. Healthcare facilities are increasingly complex, and their successful operation requires a deep understanding of not only clinical matters but also financial management, policy development, and staff oversight. Professionals who can navigate these complexities effectively have the opportunity to make a significant impact on the success of these facilities while enjoying financial rewards.

For example, you could step into a role such as Chief Medical Officer (CMO), where you would guide the clinical operations of a healthcare facility. In this role, you would be responsible for setting and enforcing clinical standards, managing medical staff, and ensuring that patient care aligns with regulatory guidelines. By bringing both your medical and managerial insights to the table, you can streamline operations and help healthcare organizations deliver better patient outcomes efficiently. This role directly influences the quality of care patients receive, which can be both professionally rewarding and financially advantageous.

Another opportunity lies in consulting services. Healthcare organizations often seek expert guidance to help them navigate challenges such as reducing operational costs, improving patient care, and enhancing revenue streams. As a consultant, you could offer strategic advice based on industry best practices, enabling healthcare providers to optimize their operations. For instance, you might assist a hospital in implementing a new electronic health record system, helping

streamline patient data management while ensuring compliance with healthcare regulations.

Consulting services can also encompass medicolegal expertise. Providing testimony as a medical expert in malpractice cases is another way to use your medical knowledge to provide a valuable service. By offering impartial and truthful expert testimony, you can play a crucial role in ensuring justice in these complex cases. For example, you might be called to testify about whether a particular treatment met the standard of care in a specific situation. This niche field requires both detailed knowledge and the ability to communicate complex medical information clearly, making it a highly respected and rewarding path.

Furthermore, many professionals provide administrative and consultative services through private practices or firms, allowing them to work with multiple clients and organizations. This setup can provide flexibility, exposure to diverse challenges, and the chance to have a broader impact on the industry. Whether it's offering guidance on improving operational efficiency or navigating regulatory changes, these roles offer a platform for experienced healthcare professionals to contribute their expertise meaningfully while enjoying significant financial rewards.

In sum, leveraging your medical expertise for administrative and consultative purposes allows you to play a pivotal role in improving healthcare systems. By helping organizations navigate operational complexities, optimizing costs, and ensuring high standards of patient care, you can achieve professional fulfillment while also reaping financial benefits.

6 - Capitalize on Ambulatory Surgery Centers:

Investing in ambulatory surgery centers (ASCs) is a golden opportunity for those looking to capitalize on the healthcare sector. ASCs, which specialize in providing same-day surgical care, are increasingly sought after due to their cost-effectiveness, efficiency, and focus on patient convenience. The COVID-19 pandemic underscored the value of ASCs, as more patients sought care in private settings outside traditional hospital environments, thus accelerating the demand for these facilities.

The intricacies involved in conceptualizing, establishing, credentialing, and managing an ASC can be challenging, but they also offer substantial returns for those willing to navigate them. ASCs require compliance with stringent regulatory standards, particularly regarding surgical safety and quality care. For example, obtaining accreditation from organizations like the Accreditation Association for Ambulatory Health Care (AAAHC) or The Joint Commission can lend credibility and ensure compliance with the highest standards.

Physicians can consider a range of investment models for ASCs. One approach, and this is how I established my brand in the Midwest, is to create a physician-owned ASC, where a group of surgeons pools resources to build and manage the center. This model allows physicians to retain full control over the facility's operations and strategic direction, thus aligning clinical goals with business objectives. For instance, a group of orthopedic surgeons might open an ASC specializing in joint replacements and sports medicine procedures, tailoring services to their expertise and local demand.

Another example is investing in joint ventures with hospitals or healthcare systems. I am not a big proponent of this option because it inevitably leads to a loss of autonomy, but it is worth mentioning. These partnerships blend the clinical expertise of physicians with the operational infrastructure of hospitals, creating synergies that enhance the efficiency and reach of the ASC. In this model, physicians benefit from the hospital's broader referral network and administrative support, while the hospital gains a valuable outpatient service that complements its broader care network.

ASCs also present investment opportunities for non-clinicians through private equity or venture capital. These investors often seek ASCs due to their potential for high returns and scalability. For instance, a private equity firm might invest in a network of ASCs, implementing standardized practices across facilities to improve efficiency and profitability. Such investments also drive consolidation in the sector, as investors seek to build portfolios of high-performing centers.

In addition to economic benefits, ASCs offer the satisfaction of improving patient care. They provide a more personalized and efficient experience compared to hospitals, often leading to higher patient satisfaction. ASCs specialize in specific procedures, resulting in streamlined workflows that minimize wait times and enhance quality. This model also reduces the risk of hospital-acquired infections, further improving patient outcomes.

Ultimately, investing in ASCs requires a thorough understanding of regulatory requirements, market demand, and clinical workflows. However, for those who can navigate these challenges, the rewards are significant. ASCs represent a rapidly growing segment of the healthcare sector, offering substantial opportunities for financial growth while contributing to the evolution of patient-centered care.

7 - Launch a Pharmacy:

Entering the pharmacy business presents a compelling opportunity due to the persistent and inevitable need for healthcare interventions. By establishing a pharmacy, you are entering an industry where demand remains consistent, irrespective of economic fluctuations. This reliability is anchored in the fundamental role pharmacies play in dispensing essential medications and medical supplies that support patient recovery and treatment.

Launching a pharmacy requires meticulous planning and investment in the necessary infrastructure. This includes securing a location with adequate space, obtaining required licenses, and establishing reliable supply chains for pharmaceuticals and medical supplies. Furthermore, the business must comply with regulations regarding prescription drugs, including controlled substances, to maintain legal and ethical standards.

A notable example of a successful pharmacy venture is the establishment of specialized pharmacies that cater to specific medical needs, such as compounding pharmacies. These

businesses customize medications to meet unique patient requirements, which is not possible with mass-produced pharmaceuticals. For instance, a compounding pharmacy might formulate medications for patients with allergies to certain ingredients in standard medications, or for pediatric patients who require precise dosages.

Another lucrative area is mail-order or online pharmacies. The convenience and efficiency of home delivery have led to a surge in demand for these services, especially in the wake of the COVID-19 pandemic. Patients with chronic conditions, such as diabetes or hypertension, can receive regular shipments of their medications, reducing the need for frequent trips to a physical pharmacy. Establishing a reliable online pharmacy requires a robust logistics network and a user-friendly digital platform, but the potential for growth is substantial.

In addition to traditional dispensing services, pharmacies can diversify revenue streams by offering value-added services like vaccination clinics, health screenings, and medication therapy management. For instance, a pharmacy might establish a vaccination program that not only dispenses flu shots but also offers COVID-19 and other routine vaccinations, increasing its appeal as a convenient, one-stop health destination.

Pharmacies that align closely with healthcare providers can also create symbiotic relationships. For example, a pharmacy located within or near a medical clinic benefits from a steady stream of patients and can provide specialized services tailored to the clinic's patient population. By collaborating with physicians to ensure patients receive comprehensive care, pharmacies can enhance medication adherence and patient outcomes.

Launching a pharmacy business is not without challenges. It requires a solid understanding of pharmaceutical regulations, supply chain management, and customer service. However, with the right planning and execution, it offers a stable and potentially lucrative opportunity. The global pharmaceuticals market is projected to continue growing, driven by aging populations and increased access to healthcare, positioning pharmacies at the heart of this growth trajectory.

By establishing a pharmacy, you not only contribute to the vital task of providing essential healthcare services but also align yourself with a business that is intrinsically linked to the ongoing need for medical care.

8 - Establish Your Own Laboratory:

The landscape of laboratory services has evolved significantly, particularly in the wake of the COVID-19 pandemic. Laboratories became pivotal in mass testing efforts, with demand skyrocketing for diagnostic services. Those strategically positioned during this period saw significant financial gains, underscoring the potential profitability of owning a laboratory business.

Establishing a laboratory requires significant planning, investment, and regulatory compliance. Start by identifying the type of laboratory you wish to establish. It could specialize in clinical diagnostics, research, toxicology, or pathology, depending on your target market and expertise. For example, a clinical diagnostics laboratory focused on infectious diseases could have a substantial impact, given the current focus on public health and preventive care.

Securing appropriate licensing and accreditation is paramount. Laboratories must adhere to rigorous standards set by regulatory bodies such as the Clinical Laboratory Improvement Amendments (CLIA) in the United States. Accreditation from organizations like the College of American Pathologists (CAP) can also enhance credibility, signaling adherence to high-quality standards.

One notable example is the rise of high-throughput testing facilities during the pandemic. Laboratories like Quest Diagnostics expanded rapidly to accommodate the surge in demand for COVID-19 testing, offering molecular, antigen, and antibody tests. This expansion highlighted the importance of scalability in laboratory operations, demonstrating how swift adaptation to changing healthcare needs can result in substantial growth.

Another lucrative area is specialized testing services. Genetic testing labs, for example, have seen increasing demand as personalized medicine gains traction. Establishing a genetics lab requires investment in sophisticated equipment and expertise in genetic analysis, but the potential to provide critical insights into hereditary diseases and personalized treatment plans is immense.

In addition to standard diagnostic services, laboratories can diversify revenue streams through research partnerships. Collaborating with pharmaceutical companies or academic institutions on clinical trials or experimental research can provide stable income and foster innovation. A laboratory could partner with a biotech firm to analyze samples from patients in a clinical trial, providing crucial data that supports drug development.

The post-COVID-19 world emphasizes the importance of robust diagnostic services, and the laboratory industry is poised for continued expansion. Increased awareness of public health and preventive care will likely maintain the high demand for laboratory testing. Beyond infectious diseases, chronic conditions like diabetes and cardiovascular diseases also require regular monitoring, further boosting the need for diagnostic services.

Entering the laboratory business involves high upfront costs and complex regulatory compliance, but the potential rewards are significant. By identifying a niche market and investing in high-quality services, you can position your laboratory to benefit from the continued growth in diagnostic services. Whether focusing on clinical diagnostics, specialized testing, or research, a well-established labora-

medicaldevicedepot.com

3 WAYS TO START IMMEDIATELY INCREASING REVENUE

1 Neuro-Cognitive Testing

4019

- Medicare mandates yearly cognitive assessment
- Takes 10-15 minutes to prep patient, 20 minutes to test
- Analyzes: brain health (EEG), brain processing speed (Evoke Potentials), heart health (EKG), mental health (neuropsychology)
- **Reimburses using 6 CPT codes, National Average = $750 - $1000 per test**
- Each test is processed into a fully-finished, clinically actionable report
- Easy to understand biomarkers facilitate more informed medical interventions, such as biofeedback

2 ANS Testing

(can be combined with SUDOMOTOR into 1 full system)

4020

- Takes less than 10 minutes to perform, software provides verbal cues
- Tests for autonomic balance, vascular health, physical/mental stress, peripheral nerve health and other critical hidden risk factors
- **Reimburses $170/test using 3 CPT codes**
- Provides a 1 page summary up to a full 24 page comprehensive report



3 SudoMotor Testing

4021

(can be combined with ANS into 1 full system)

- Takes 3 minutes to analyze a patients' hands and feet
- Provides a 1 page summary report
- Assesses peripheral nerve health (c-fiber function) and asymmetry between each hand and foot
- **Reimburses $130/test (national average)**

Medical Device Depot © Inc.

Toll Free 877-646-3300

SITEWIDE SALE

COUPON CODE **MDDSAVE**

for additional savings at checkout!

SPIRE INTEGRATED SOLUTIONS

Medical Device Depot® is part of the Spire Integrated Solutions family.

© 2021 Medical Device Depot ALL RIGHTS RESERVED

tory can be an integral part of the healthcare system and a profitable venture in its own right.

9 - Open Your Own Imaging Center:
Opening an imaging center is a significant venture that requires careful planning, significant investment, and a commitment to providing high-quality diagnostic services. The increasing importance of imaging in medical diagnostics offers a substantial opportunity for those willing to navigate the complexities of this business.

Begin by conducting a comprehensive market analysis to understand the demand for imaging services in your target area. This analysis should identify the types of imaging most needed, assess the competitive landscape, and pinpoint gaps in existing services. For example, if your target area has a high prevalence of orthopedic cases, focusing on modalities like MRI and CT scans could cater to a significant portion of the patient population.

Securing a suitable location is crucial to the center's success. It should be accessible to patients and referring physicians, have ample parking, and comply with zoning regulations for healthcare facilities. For instance, locating the center near a medical campus or hospital can increase patient referrals and enhance collaboration with other healthcare providers.

The equipment is another critical aspect. Acquiring state-of-the-art imaging devices involves substantial costs, but it's necessary to provide high-quality services. Consider leasing equipment or purchasing certified pre-owned machines to reduce initial costs without compromising quality. For example, a refurbished MRI machine could offer similar functionality to new models at a fraction of the price.

Obtaining the necessary licenses and accreditations is next. Compliance with state healthcare regulations is essential, and obtaining accreditation from recognized bodies like the American College of Radiology (ACR) can enhance your center's credibility and patient trust. Accreditation demonstrates a commitment to quality and safety, often influencing patients' and physicians' choices in healthcare providers.

Recruiting a skilled team is vital for the imaging center's operational efficiency and patient care. Hiring experienced radiologists, technicians, and support staff ensures accurate diagnostics and smooth operations. Implementing a robust billing system is also crucial, as is establishing relationships with insurance providers to streamline payment processes and ensure timely reimbursement.

Finally, developing a comprehensive marketing strategy is essential for promoting your services to the local community and healthcare providers. Attending medical conferences, joining professional networks, and using digital marketing strategies can increase the center's visibility. Building partnerships with local physicians is also crucial, as they often guide patients toward specific imaging centers based on service quality and reliability.

Consider how RadNet, one of the largest outpatient imaging networks in the United States, expanded through strategic acquisitions and partnerships. By aligning with local physicians and offering a broad range of imaging services, RadNet established a network that ensures both patient convenience and high-quality diagnostics.

Opening an imaging center is a demanding endeavor, but it offers substantial rewards for those who execute it successfully. By focusing on market needs, investing in the right equipment and personnel, and building strong professional relationships, you can establish a thriving imaging center that contributes meaningfully to patient care while also being a profitable venture.

Conclusion:
This brief overview highlights the variety of healthcare investment opportunities available to new investors. Each option could be detailed in an entire book, but that's beyond the scope of this series of articles. Therefore, I will provide a concise description of each option. In the upcoming articles, I'll delve deeper into each of these business opportunities to provide more detailed insights.

As Nelson Mandela wisely noted, "It always seems impossible until it's done." Starting a new business can feel like a formidable challenge, but taking that initial step often reveals that the journey is more manageable than anticipated.



Spanning two decades, Dr. Shakeel Ahmed, a gastroenterologist turned healthcare mogul, has transformed his vision into the Midwest's leading Ambulatory Surgery Centers network. His dual expertise in medical administration and surgical execution-gained from years of frontline experience-has been pivotal in mastering the complexities of the healthcare sector. Dr. Ahmed's notable contributions extend beyond the ASC sphere; he has played a key role in developing a comprehensive healthcare network, including a range of medical facilities, diagnostic centers, and surgical establishments across several states. His literary contributions includes 6 published books alongside hundreds of articles in prestigious national and international journals. He is a consultant for multiple governments on healthcare development and works as an advisor to various governments across four continents in the establishment of outpatient surgery centers.

Newman Medical


PERIPHERAL ARTERY DISEASE

(PAD) is an often silent condition where narrowed arteries reduce blood flow to the legs, causing symptoms like leg pain, numbness, and slow-healing wounds.

HOW MANY OF THESE PATIENTS DO YOU HAVE?

- Diabetics
- Smokers
- Over age 65

1 out of 3 HAS PAD



DON'T LET PAD SNEAK UP ON YOU OR THESE PATIENTS.
50% report no symptoms, while those that do attribute their pain to arthritis or "old age".

THESE PATIENTS *TRUST YOU* TO FIND THEIR PAD
before they have a heart attack, stroke, or even die. PAD also leads to significant disability and reduced quality of life.

INTRODUCING SIMPLEABI-Q: A USER-FRIENDLY SOLUTION FOR EARLY PAD TESTING.

EASY
- No Doppler or vascular anatomy knowledge necessary.
- Can be done in five minutes or less by any staff member.
- Non-invasive, patient-friendly test.

ACCURATE
- Accuracy equal or better than Doppler ABI.
- Useful for diabetics with calcified arteries.

REIMBURSABLE
- **Great ROI:** the typical internist has 800 Medicare patients, per ACP.
- Testing five patients per week can pay for the system in less than two months.
- CPT 93923, with a national average of $142/exam.



Newman Medical

With over 40 years of experience in diagnostic ultrasound, Newman Medical is a trusted leader in vascular testing solutions. Newman's ABI-Q rapid-test system epitomizes their commitment to pioneering technology. Built on integrity and expertise, count on Newman Medical for precise, rapid, and reliable vascular testing solutions.

CONTACT US NOW

to learn how early PAD detection benefits both your patients and your practice.

Book a free live demo of the simpleABI-Q:

NEWMAN-MEDICAL.COM | 800-267-5549 | INFO@NEWMAN-MEDICAL.COM



4023

BIOFIRE SPOTFIRE

From bioMerieux

bioMérieux knows that an evolving world deserves evolved diagnostics. Our latest innovation, the BIOFIRE® SPOTFIRE® Respiratory Solution, is the first FDA-cleared and CLIA-waived COVID-19 testing solution. The BIOFIRE® SPOTFIRE® System is an easy-to-use system that runs the BIOFIRE® SPOTFIRE® Respiratory (R) Panel. Benefits of the SPOTFIRE Respiratory Solution include: 15 respiratory targets on 1 PCR test with results in about 15 minutes; minimal benchtop space with vertical scalability up to four modules; easy to use with an intuitive user interface.

View Brochures, Videos & More at POR.io
Enter Number **4023** in the Search Area

ACUCY INFLUENZA A&B TEST

From Sekisui Diagnostics

The Acucy™ Influenza A&B Test is for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. Utilizing the Acucy™ Reader in either the point-of-care or laboratory setting, workflow flexibility is achieved with both Read Now and Walk Away features. The combination provides clinicians with standardized and definitive result interpretation.

View Brochures, Videos & More at POR.io
Enter Number **4024** in the Search Area



4024



4025

OSOM ULTRA PLUS FLU A&B TEST

From Sekisui Diagnostics

Stronger Clinical Performance Takes Lateral Flow Testing To The Next Level. Providing superior rapid results at the point-of-care. Fast, easy, cost effective so you can test and treat in one visit.

- High Performance- Equivalent or exceeding the performance of reader devices, without the need for an instrument
- Results in 10 minutes
- OSOM® Custom Care- Exceptional Support/Training by licensed medical technologists and experienced healthcare professionals
- Made in the USA

View Brochures, Videos & More at POR.io
Enter Number **4025** in the Search Area



STATE-OF-THE-ART BENCHTOP CBC ANALYZER

From Sight Diagnostics

OLO® by Sight Diagnostics® is a state-of-the-art benchtop CBC analyzer that leverages AI, spectroscopy, and digital fluorescent microscopy to provide lab-grade results through full blood sample digitization. OLO offers 19 CBC parameters, including a 5-part white blood cell differential and 14 distinct flags. It handles venous and capillary blood samples with a minimum of 27 µL, and is suitable for children as young as three months. OLO's unique cartridge-based technology, free from liquid reagents, and its internal controls offer easy maintenance, room-temperature storage, reduced operational overhead, and IQCP- eligibility.

OLO is FDA 510(k) cleared for use in moderately complex laboratories. For full indications for use and safety information, please refer to the Quality and Compliance page at www.sighdx.com.

View Brochures, Videos & More at POR.io
Enter Number **4026** in the Search Area

TURN SMALL PLACES INTO SMART SPACES

From Abbott

With reduced budgets, shrinking laboratory space and staffing challenges, many laboratories need a solution that lets them work smarter with less. The CELL-DYN Emerald 22 AL is a full performance, automated optical 5-part differential analyzer that delivers smarter results for small to midsize clinical laboratories.

- Compact Design
- Walkaway Functionality
- Ease Of Use
- Smart Safety Features

View Brochures, Videos & More at POR.io
Enter Number **4027** in the Search Area





MICROS HEMATOLOGY ANALYZER WITH 3-PART DIFFERENTIAL PLUS THE LITEDM

From HORIBA Medical

Is it viral or bacterial? A CBC with 3-part differential can provide the clues to help distinguish between viral and bacterial infections before you decide to treat. The Micros 60 Hematology analyzer provides a CBC with 3-part Diff result in less than 60 seconds using only 10 µL of sample. Connect to the Lite^{DM} Patient Data Management System for an affordable way to consolidate patient results to one report.

View Brochures, Videos & More at POR.io
Enter Number **4028** in the Search Area

PERIPHERAL ARTERIAL DISEASE



4029

QUANTAFLO® PAD

From Semler Scientific

QuantaFlo® PAD is an easy to use, accurate, point of care, non-invasive solution that aids in the early detection of peripheral arterial disease (PAD). This FDA cleared device can be administered by a medical aide in less than 5 minutes. As published in the Journal of Vascular Surgery and the American Journal of Preventive Medicine, QuantaFlo detected undiagnosed PAD in 31.6% of patients +65.1 QuantaFlo is portable and integrates with other technologies and platforms. It is ideal for both home and clinic environments.

1. Smolderen KG, Ameli O, Chaisson CE, Heath K, Mena-Hurtado C. Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events, AJPM Focus (2022), https://doi.org/10.1016/j.focus.2022.100016

View Brochures, Videos & More at POR.io
Enter Number **4029** in the Search Area

PAD TESTING SYSTEMS IDEAL FOR PRIMARY CARE TO VASCULAR SPECIALISTS

from Newman Medical

Your Patients Trust YOU To Find Their Peripheral Artery Disease
- High-risk patients include those over 65, diabetics, and smokers.
- If left untreated, 25% of patients with PAD will experience a heart attack or stroke within 5 years.
- PAD symptoms are often mistaken for arthritis or old age.

The simpleABI Cuff-Link System is Easy to Learn and Use.
- With a push-button remote, automatic calculations, and waveforms, it's incredibly user-friendly.
- Reports are straightforward to save and share since the system is PC-based.

Outstanding Value and Reimbursements
- The system pays for itself in less than a year with just one test per week.
- Medicare reimbursements vary by exam and location, averaging from $91 to $174.

View Brochures, Videos & More at POR.io
Enter Number **4030** in the Search Area

4030



SYNDROMIC TESTING



4031

BIOFIRE® FILMARRAY® TORCH

From bioMérieux

The BIOFIRE® FILMARRAY® TORCH is a fully integrated, random, and continuous-access system designed to meet your laboratory's syndromic infectious disease testing needs. The benchtop footprint of the BIOFIRE TORCH saves precious lab space, and its scalability meets high throughput demands. BIOFIRE® FILMARRAY® Link Software automatically uploads patient results. Fully compatible with all BIOFIRE® FILMARRAY® Panels intended for use in CLIA-moderate settings, the BIOFIRE TORCH helps you maximize efficiency and productivity.

View Brochures, Videos & More at POR.io
Enter Number **4031** in the Search Area



EASY ORDERING

QUICK DELIVERY

A wide range of equipment for physicians and healthcare professionals.

Medical Device Depot ©Inc.

Top brands always at the best price.

sdi DIAGNOSTICS

4032





4033

defibtech



4034



MAICO

4035



Nasiff Associates, Inc.

4036

CLINTON INDUSTRIES INC.



4037

WelchAllyn



4038



ADC

4039

SITEWIDE SALE

COUPON CODE **MDDSAVE**

for additional savings at checkout!

SPIRE INTEGRATED SOLUTIONS Medical Device Depot®, Inc. is part of the Spire Integrated Solutions family.

© 2022 . Medical Device Depot . ALL RIGHTS RESERVED

Medical Device Depot ©Inc.

Toll Free 877-646-3300

medicaldevicedepot.com

CLINICIANS' CHOICE FOR EVIDENCE-BASED CBD

At NextEvo Naturals, we champion the integration of nature's profound healing capabilities with cutting-edge scientific research. It is well documented CBD contains properties of anti-inflammatory and anxiolytic effects. However, CBD is not well absorbed, so we use natural pharmaceutical techniques to deliver superior absorption and precision dosage each and every time.

Our mission? To unlock the full potential of CBD, ensuring safety, efficacy, and transparency at every step.



Clinically Proven Formulas

We employ proprietary technology to enhance the bioavailability of our CBD, ensuring maximum absorption and effectiveness.

Rigorously Tested

Rigorously tested and verified by third-party labs, our products meet the highest standards for manufacturing, purity, and potency.

Leading With Science

We completed a multi-day ascending dose trial to measure the immunomodulatory impacts of high absorption CBD.

CLINICAL-STRENGTH PRODUCTS

NEW:
6x Absorption Formula



Clinical Strength Daily Wellness Capsules 80mg

Deep Penetrating Cream



Maximum Strength Revive + Restore 5% CBD Cream

Learn More

professionals.nextevo.com

CLINICIANS' CHOICE

CBD PRODUCTS CREATED TO SOLVE CLINICIANS' ISSUES.

NextEvo™ Naturals pioneers a new era in CBD.



NextEvo™
NATURALS



SCREENING DIABETIC PATIENTS WITH WOUNDS FOR PAD AND NEUROPATHY IS A STANDARD OF CARE

BY DR. JAY LONG, MD, RETIRED VASCULAR SURGEON, MEDICAL DIRECTOR – SEMLER SCIENTIFIC, INC.

A major lower-extremity amputation has been reported to be the most feared complication by patients experiencing diabetic foot problems.[1] The statistics surrounding diabetic foot ulcers (DFU) and potential subsequent amputations are staggering.

- Foot ulcers are present in 1 out of 10 patients with diabetes[2]
- Underlying neuropathy contributes to more than 60% of diabetic foot ulcers[3]
- A foot ulcer is the initial event that leads to over 85% of major amputations among people with diabetes[4]
- Patients with both diabetes mellitus and peripheral arterial disease (PAD) are four times more likely to undergo an amputation than those with PAD alone.[5]

Patients with diabetes experience a significantly higher rate of major limb amputations compared to non-diabetics. The disparity in amputation rates between these cohorts underscores the critical need for comprehensive management of diabetes and its associated risk factors.

Primary care practitioners play a crucial role in helping diabetic patients with non-healing wounds by identifying and managing peripheral neuropathy and peripheral arterial disease, both of which are major contributors to wound progression.

While implementing tighter control of A1C levels, blood pressure, cholesterol, and other risk factors like smoking can contribute to long-term reductions in morbidity and mortality, they do not immediately improve wound healing. Acutely managing diabetic wounds by controlling the presence of infections and removing necrotic and infected material is critical. These steps have the potential to decrease the deterioration of the wound; however, neither will independently improve the likelihood of wound healing, especially with underlying PAD.

Additionally, screening for PAD by palpating pulses alone is not sufficient to confirm adequate blood flow for wound healing. The use of cuff-based ABI is a common tool to assist with diagnosing PAD, but it has limitations when measuring the characteristically non-compressible arteries of a diabetic patient. An alternative diagnostic tool that is not limited by arterial calcification is the QuantaFlo device which uses volume flow technology to produce a digital ABI reading and is an excellent screening test for PAD.

Referring patients to a dedicated specialty team can also significantly reduce complications and the risk of amputations for a non-healing wound. This team typically includes specialists in wound care, diabetes, podiatry, infectious disease, and vascular. Their collective expertise can provide comprehensive care tailored to the specific needs of diabetic patients with chronic wounds. PAD can be treated by rerouting blood flow, either with bypass surgery or through a minimally invasive procedure. Improving the flow of oxygen and nutrients to an ulcer within eight weeks of evaluation can enhance ulcer healing prospects.[6]

Diabetic foot ulcers are a serious complication of diabetes that can put patients at significant risk of amputation, particularly when combined with neuropathy and peripheral artery disease (PAD). Diabetic neuropathy increases the chances that a patient will develop a DFU due to the loss of protective sensation in the limb, making it difficult for the patient to notice the wound in a timely manner. Additionally, a diagnosis of PAD with a DFU is associated with numerous negative implications for the patient, including the need for advanced and intensive healthcare, risk of limb loss, and mortality.

This combined pathology poses significant challenges for healthcare systems struggling with increased prevalence of diabetes and its chronic complications. By addressing both neuropathy and PAD early on and involving a specialized care team, primary care practitioners can potentially improve outcomes and quality of life for diabetic patients with non-healing wounds.

References

1. Wukich, D.K., Raspovic, K.M., & Suder, N.C. (2018). Patients with diabetic foot disease fear major lower-extremity amputation more than death. Foot & Ankle Specialist, 11(1), 17-21. https://doi.org/10.1177/1938640017694722

2. Wu, S.C., Driver, V.R., Wrobel, J.S., & Armstrong, D.G. (2007). Foot ulcers in the diabetic patient, prevention and treatment. Vascular Health and Risk Management, 3(1), 65-76. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994045/

3. Clayton, W.J, & Elasy, T.A. (2009). A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Clinical Diabetes, 27(2), 52–58. https://doi.org/10.2337/diaclin.27.2.52

4. Brownrigg, J.R.W., Apelqvist, J., Bakker, K., Schaper, N.C., & Hinchliffe, R.J. (2013). Evidence-based management of PAD & the diabetic foot. European Journal of Vascular and Endovascular Surgery, 45(6), 673-681. https://doi.org/10.1016/j.ejvs.2013.02.014

5. Barnes, J.A., Eid, M.A., Creager, M.A., & Goodney, P.P. (2020). Epidemiology and risk of amputation in patient with diabetes mellitus and peripheral artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 40(8), 1808-1817. https://doi.org/10.1161/ATVBAHA.120.314595

6. Elgzyri, T., Larsson, J., Nyberg, P., Thörne, J., Eriksson, K-F., & Apelqvist, J.(2014). Early revascularization after admittance to a diabetic foot center affects the healing probability of ischemic foot ulcer in patients with diabetes. European Journal of Vascular and Endovascular Surgery, 48(4), 440-446. https://doi.org/10.1016/j.ejvs.2014.06.041



Secrets Cap Cana:

DISCOVERING PARADISE

BY JEN HELMLE



Nestled along the picturesque coastline of the Dominican Republic, within the exclusive enclave of Cap Cana, lies a sanctuary of luxury and tranquility – Secrets Cap Cana. Enveloped by lush tropical landscapes and caressed by the gentle Caribbean breeze, this all-inclusive haven offers an unparalleled escape for discerning travelers seeking a perfect blend of relaxation, adventure, and indulgence.

Upon arrival at Secrets Cap Cana, guests are greeted with a warm welcome and ushered into a world of refined elegance. The resort's architecture seamlessly integrates with the natural surroundings, featuring Spanish Colonial-style buildings adorned with intricate details and surrounded by manicured gardens. The ambiance is one of serenity and sophistication, setting the stage for an unforgettable experience from the moment you arrive.

Accommodations at Secrets Cap Cana are nothing short of extraordinary, with a range of luxurious options to suit every preference. From spacious suites boasting stunning ocean views to opulent villas with private plunge pools and expansive terraces, each room is meticulously appointed with modern amenities and elegant furnishings. Sink into plush bedding, unwind in the oversized soaking tub, or step out onto your private balcony to savor the breathtaking vistas of the Caribbean Sea. For those seeking relaxation, the resort's pools provide the perfect retreat. The main pool area features cascading waterfalls, swim-up bars, and plenty of lounge chairs for soaking up the sun. For a more serene experience, the infinity pool offers uninterrupted views of the ocean, creating an atmosphere of pure bliss. And of course, the stunning Juanillo Beach beckons just steps away, with its powdery white sands and crystal-clear waters inviting guests to unwind and soak up the tropical ambiance.

But the allure of Secrets Cap Cana extends far beyond its luxurious accommodations and pristine beaches. The resort offers a wealth of activities and experiences to suit every taste. Thrill-seekers can embark on exciting adventures such as deep-sea fishing expeditions, catamaran cruises, or zip-lining through the lush jungle canopy. Golf enthusiasts will delight in the nearby Punta Espada Golf Course, a Jack Nicklaus signature course renowned for its challenging fairways and breathtaking ocean views.

For those craving cultural immersion, the surrounding area offers a treasure trove of experiences waiting to be discovered. Take a guided tour of the Indigenous Eyes Ecological Park and Reserve, where you can explore lush tropical forests, sparkling lagoons, and hidden caves. Or, venture to Altos de Chavón, a charming replica of a 16th-century Mediterranean village perched atop the cliffs overlooking the Chavón River, where you can explore artisan shops, galleries, and historic landmarks.

Of course, no visit to Secrets Cap Cana would be complete without indulging in the culinary delights that await you. The resort boasts an array of gourmet restaurants, each offering a unique dining experience inspired by flavors from around the world. Begin your day with a leisurely breakfast at "Barefoot Grill," where you can enjoy made-to-order omelets, fresh fruit, and artisan pastries while soaking in panoramic views of the



beach. For lunch, head to "Market Café," the resort's buffet-style restaurant, where you can feast on an array of international dishes, including fresh seafood, grilled meats, and savory soups and salads.

As evening falls, embark on a culinary journey at one of Secrets Cap Cana's specialty restaurants. Indulge in the rich flavors of Italy at "Portofino," where you can savor homemade pasta dishes, succulent seafood, and decadent desserts paired with fine wines. For a taste of the Caribbean, make reservations at "Blue Water Grill," where you can dine al fresco on freshly caught seafood and island-inspired dishes while enjoying panoramic views of the ocean.

After a day of exploration and indulgence, retreat to the sanctuary of the resort's spa, where a world of relaxation awaits. The Secrets Spa by Pevonia® offers a comprehensive menu of rejuvenating treatments designed to pamper the body and soothe the soul. Choose from a variety of massages, facials, and body wraps, all performed by skilled therapists using natural ingredients sourced from the Dominican Republic. For the ultimate indulgence, opt for a couples' massage in one of the spa's serene treatment rooms, complete with private Jacuzzi and ocean views. As tensions melt away and your senses are heightened, allow yourself to be transported to a state of pure bliss.

As the sun sets on another perfect day in paradise, gather with fellow guests for an evening of entertainment, from live music performances to themed parties that will keep you dancing into the night. Or, if you prefer a more intimate setting, retreat to the privacy of your suite and toast to another unforgettable day in paradise.

In every corner of Secrets Cap Cana, luxury, adventure, and romance intertwine to create an experience unlike any other. Whether you seek relaxation, adventure, or cultural exploration, this hidden oasis promises to exceed your every expectation. It's no wonder that Secrets Cap Cana has been recognized with numerous prestigious awards, including the highly-coveted AAA Five Diamond Award is given to resorts that exceed the highest standards of overall quality, range of facilities and level of services offered on property, based on rigorous AAA standards. So pack your bags, leave your worries behind, and embark on a journey to discover Secrets Cap Cana – where paradise awaits!!







OSOM® BVBLUE®

From Sekisui Diagnostics

The OSOM® BVBLUE® detects elevated vaginal fluid sialidase activity, an enzyme produced by bacterial pathogens associated with bacterial vaginosis including Gardnerella, Bacteroides, Prevotella and Mobiluncus. OSOM® BVBLUE® is more sensitive than Amsel criteria providing physicians with a more accurate diagnosis to treat and minimize serious health consequences such as early spontaneous preterm births and miscarriage.

View Brochures, Videos & More at POR.io
Enter Number **4040** in the Search Area

OSOM® TRICHOMONAS RAPID TEST

From Sekisui Diagnostics

The OSOM® Trichomonas Rapid Test is intended for the qualitative detection of Trichomonas vaginalis antigens from vaginal swabs or from the saline solution. The OSOM® Trichomonas Rapid Test is a CLIA-waived rapid test available today. OSOM® Trichomonas is more sensitive than wet mount due to the assay being able to detect viable and non-viable organisms which offers significant benefits to the patient and clinician alike.

View Brochures, Videos & More at POR.io
Enter Number **4041** in the Search Area





ULTRA HCG COMBO TEST


From Sekisui Diagnostics

The OSOM® Ultra hCG Combo test is a simple immunoassay for the qualitative detection of human chorionic gonadotropin (hCG) in serum or urine for the early confirmation of pregnancy. Internal studies have confirmed that the OSOM® Ultra hCG Combo test does not have a false negative result from hCG variants providing physicians with a higher level of confidence.

View Brochures, Videos & More at POR.io
Enter Number **4042** in the Search Area

LUXURY TRAVEL DESTINATIONS | SPECIAL OFFERS | REVIEWS


MDescapes



PHYSICIANSOFFICERESOURCE.COM/MDESCAPES/
INSTAGRAM @MDESCAPES









Our goal is to REWARD YOU

MDescapes features exclusive luxury travel discounts and offers! Our goal is to reward you, the healthcare professional, and help provide the rest, adventure, and memoires that accompany a luxury vacation.

FOUR SEASONS NEVIS

FOUR SEASONS PUNTA MITA

FOUR SEASONS NEW ORLEANS

FOUR SEASONS SANTA FE

CARTON HOUSE

SANDESTIN GOLF AND BEACH RESORT

AND MORE

—


FIND YOUR ESCAPE AT

PhysiciansOfficeResource.com/MDescapes

TOXICOLOGY SCREENING

SIMPLIFIED.

Comprehensive toxicology menu now with **14 CLIA[1] categorized moderate complexity assays.**



IMMTOX™ 270

BENCHTOP ANALYZER

Toxicology screening solutions for physician offices, pain management, treatment centers and laboratories testing 200+ patient samples/mo.

Scan this QR code to view the ImmTox™ 270 product video

MODERATE COMPLEXITY ASSAYS – FDA 510(K) CLEARED	
6-acetylmorphine (6-AM Heroin metabolite)	EDDP (Methadone metabolite)
Amphetamine	Fentanyl*
Barbiturates	Methamphetamine
Benzodiazepines	Opiates
Benzoylecgonine (Cocaine metabolite)	Oxycodone
Buprenorphine	Phencyclidine (PCP)
Cannabinoids (THC)	Tramadol

CONTACT ABBOTT CLINICAL LAB SOLUTIONS

855-425-9428 | CLS_SALES@ABBOTT.COM

1. Clinical Laboratory Improvement Amendments (CLIA) / * SEFRIA Fentanyl

© 2022 Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners. Any photos displayed are for illustrative purposes only. COL-09575 v3 12/22

Abbott